Lawsuit Overview - The class action lawsuit against BioAge Labs alleges violations of the Securities Act of 1933, specifically that the IPO offering documents contained materially false and/or misleading statements regarding the safety and expected results of the STRIDES clinical trial [1][3] - The lawsuit is captioned Soto v BioAge Labs, Inc, No 25-cv-00196 (N D Cal) and purchasers or acquirers of BioAge Labs stock pursuant to the IPO have until March 10, 2025 to seek appointment as lead plaintiff [1] BioAge Labs Background - BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases [2] - In its IPO on September 26, 2024, BioAge Labs sold 12 65 million shares at $18 00 per share [2] Allegations and Impact - The lawsuit alleges that on December 6, 2024, BioAge Labs announced discontinuation of the STRIDES Phase 2 study of its investigational drug candidate azelaprag due to liver transaminitis observed in some subjects [4] - Following this announcement, BioAge Labs stock price fell more than 76% and was trading at or around $5 82 per share, significantly below the $18 00 IPO price [4] Lead Plaintiff Process - Under the Private Securities Litigation Reform Act of 1995, any investor who purchased or acquired BioAge Labs stock pursuant to the IPO can seek appointment as lead plaintiff [5] - The lead plaintiff, typically the movant with the greatest financial interest, acts on behalf of all class members and can select a law firm to litigate the case [5] Robbins Geller Law Firm - Robbins Geller Rudman & Dowd LLP is representing investors in this securities fraud case [6] - The firm has recovered $6 6 billion for investors in securities-related class action cases over the last four years, including the largest securities class action recovery ever of $7 2 billion in the Enron case [6]
BIOA INVESTOR NOTICE: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit